Department of Neurology, UCSF Medical Center, USA.
Mult Scler. 2013 Jun;19(7):835-43. doi: 10.1177/1352458512471880. Epub 2013 Jan 14.
For physicians who care for patients with multiple sclerosis (MS), the use of disease-modifying therapies (DMTs) during the conception period and pregnancy raises important safety considerations. All DMTs have potential adverse effects on fertility, pregnancy outcomes, and breastfed infants. Although physicians are reluctant to prescribe DMTs to MS patients who are contemplating having a family or are already pregnant, treatment can be warranted in those who have active disease. This review assembles the most current information on the reproductive safety of approved and emerging DMTs drawn from the literature and information supplied by the manufacturers.
对于治疗多发性硬化症（MS）患者的医生来说，在受孕期和怀孕期间使用疾病修正疗法（DMT）会引发重要的安全性考虑。所有 DMT 都可能对生育能力、妊娠结局和母乳喂养婴儿产生潜在的不良影响。尽管医生不愿意给正在考虑生育或已经怀孕的 MS 患者开 DMT 处方，但对于那些患有活动性疾病的患者，治疗可能是必要的。这篇综述综合了来自文献和制造商提供的信息，对已批准和新兴的 DMT 在生殖安全性方面的最新信息进行了总结。
